Results 91 to 100 of about 39,211 (299)

CYP2D6‐Guided Opioid Therapy for Chronic Pain: A Multi‐Center Pragmatic Randomized Controlled Trial

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
The analgesic effectiveness of several opioids depends on CYP2D6‐mediated metabolism to more active opioid receptor agonists. CYP2D6 activity is impacted by genetic variability and medications that inhibit CYP2D6. We conducted a pragmatic, multi‐center, randomized, controlled trial to determine whether CYP2D6‐guided opioid prescribing improves chronic ...
Todd C. Skaar   +255 more
wiley   +1 more source

The pharmacogenomics of statins

open access: yesPharmacological Research, 2014
The statin class of cholesterol-lowering drugs have been used for decades to successfully lower plasma cholesterol concentrations and cardiovascular risk. Adverse effects of statins are generally considered mild, but increase with age of patients and polypharmacy.
Ingrid C, Gelissen, Andrew J, McLachlan
openaire   +2 more sources

Overview of Regulatory Guidelines Related to Methods and Models for Small Populations

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
This paper provides an overview of approaches and related guidelines from the EMA, FDA, and ICH that are relevant for obtaining clinical evidence for small populations to support regulatory decision making. The approaches are grouped into three categories: (1) maximizing the attainable sample size, (2) adapting the trial design to deal with a small ...
Laurens Sluijterman   +6 more
wiley   +1 more source

A Pilot Randomized Study of NAT2 and YEATS4 Pharmacogenetic Return of Results in Adults with Hypertension and African Ancestry: The GUARDD‐US PGx Study

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Almost half of individuals with hypertension fail to achieve recommended blood pressure (BP) goals. Pharmacogenetic gene‐drug interactions may alter the efficacy of antihypertensive agents. We conducted a multicenter randomized controlled sub‐study of participants (N = 1874) with hypertension and self‐reported African ancestry to determine whether ...
Philip E. Empey   +25 more
wiley   +1 more source

Perspectives on Using Pharmacogenomics to Guide Tobacco Cessation: Survey Results From an American Indian Community

open access: yesClinical and Translational Science
Pharmacogenomics research has predominantly focused on populations of European ancestry, limiting the application to diverse populations such as American Indian and Alaska Native (AIAN) communities.
Madeline L. Wichman   +10 more
doaj   +1 more source

The gut microbiome and drug‐resistant epilepsy: Microbiome–antiseizure medication interactions and implications for pharmacoresistance

open access: yesEpilepsia Open, EarlyView.
Abstract Drug‐resistant epilepsy (DRE) affects approximately one‐third of patients with epilepsy and represents a major unmet clinical need. While traditional hypotheses of pharmacoresistance have focused on alterations in drug targets, efflux transporter overexpression, and intrinsic disease severity, the gut microbiome has recently emerged as a ...
Khaled Zammar   +4 more
wiley   +1 more source

Top Three Pharmacogenomics and Personalized Medicine Applications at the Nexus of Renal Pathophysiology and Cardiovascular Medicine

open access: yes, 2011
Pharmacogenomics is a field with origins in the study of monogenic variations in drug metabolism in the 1950s. Perhaps because of these historical underpinnings, there has been an intensive investigation of 'hepatic pharmacogenes' such as CYP450s and ...
Bochud, Murielle   +8 more
core   +1 more source

Longitudinal Development of Portion Size Estimation in Patients With Anorexia Nervosa Receiving Inpatient Treatment—Evidence From Laboratory and Real‐Life Data

open access: yesEuropean Eating Disorders Review, EarlyView.
ABSTRACT Background Food intake is highly aversive for patients with anorexia nervosa (AN), and fear of weight gain is closely linked to altered eating behaviours, including reduced portion sizes. This study investigated how portion size estimation develops longitudinally in patients with AN during inpatient treatment.
Katrin E. Giel   +8 more
wiley   +1 more source

Pharmacogenomics of sickle cell disease: steps toward personalized medicine

open access: yes, 2017
Marium Husain,1 Amber D Hartman,2 Payal Desai3 1Division of Medical Oncology, 2Division of Palliative Medicine, 3Division of Hematology, The Ohio State University Wexner Medical Center, Columbus, OH, USA Abstract: Sickle cell disease (SCD) is a ...
Desai P, Hartman AD, Husain M
core  

Transforming the Landscape of Drug Innovation in AI Era: AlphaFold 3 and Beyond

open access: yesExploration, EarlyView.
Traditional drug development is time‐consuming and costly, and new tools are urgently needed to improve efficiency. This perspective reviews the considerable potential of AlphaFold 3 as a next‐generation predictive tool for drug discovery, particularly in target identification and validation, hit identification and lead optimization, and personalized ...
Songlin He   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy